WN
Therapeutic Areas
Bayer Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Xarelto (rivaroxaban) | Anticoagulation | Approved |
| Eylea (aflibercept) | Wet AMD, Diabetic Macular Edema | Approved |
| Nexavar (sorafenib) | Hepatocellular carcinoma, Renal cell carcinoma | Approved |
| Stivarga (regorafenib) | Colorectal cancer, GIST | Approved |
| Vitrakvi (larotrectinib) | TRK fusion cancers | Approved |
| Nubeqa (darolutamide) | Prostate cancer | Approved |
| Kerendia (finerenone) | Diabetic kidney disease | Approved |
| BAY 1817080 | Multiple solid tumors | Phase 1 |